Research Analysts Issue Forecasts for DNTH FY2025 Earnings

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) – Investment analysts at Cantor Fitzgerald increased their FY2025 earnings per share (EPS) estimates for shares of Dianthus Therapeutics in a research report issued to clients and investors on Thursday, March 13th. Cantor Fitzgerald analyst P. Stavropoulos now expects that the company will earn ($3.16) per share for the year, up from their prior estimate of ($3.46). The consensus estimate for Dianthus Therapeutics’ current full-year earnings is ($2.61) per share.

A number of other brokerages have also recently weighed in on DNTH. Guggenheim restated a “buy” rating and issued a $84.00 price objective on shares of Dianthus Therapeutics in a report on Wednesday, March 12th. HC Wainwright restated a “buy” rating and issued a $40.00 price target on shares of Dianthus Therapeutics in a research note on Wednesday, March 12th. TD Cowen initiated coverage on Dianthus Therapeutics in a research note on Friday, December 20th. They set a “buy” rating for the company. Wedbush reissued an “outperform” rating and issued a $36.00 target price on shares of Dianthus Therapeutics in a research note on Wednesday, March 12th. Finally, Raymond James raised Dianthus Therapeutics to a “moderate buy” rating in a research report on Thursday, December 12th. Eight investment analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Buy” and a consensus price target of $52.14.

Dianthus Therapeutics Price Performance

NASDAQ:DNTH opened at $21.97 on Monday. The firm’s 50-day moving average price is $22.44 and its 200-day moving average price is $24.76. The company has a market capitalization of $650.25 million, a PE ratio of -8.79 and a beta of 1.82. Dianthus Therapeutics has a 1-year low of $18.13 and a 1-year high of $33.77.

Dianthus Therapeutics (NASDAQ:DNTH) last posted its quarterly earnings data on Tuesday, March 11th. The company reported ($0.81) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.85) by $0.04. The business had revenue of $1.33 million during the quarter, compared to the consensus estimate of $1.40 million. Dianthus Therapeutics had a negative return on equity of 21.68% and a negative net margin of 1,250.32%.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the company. Quest Partners LLC lifted its stake in shares of Dianthus Therapeutics by 112,400.0% in the 3rd quarter. Quest Partners LLC now owns 1,125 shares of the company’s stock worth $31,000 after purchasing an additional 1,124 shares during the period. R Squared Ltd purchased a new position in shares of Dianthus Therapeutics during the 4th quarter worth $26,000. KLP Kapitalforvaltning AS bought a new stake in shares of Dianthus Therapeutics during the 4th quarter valued at $33,000. KBC Group NV purchased a new stake in shares of Dianthus Therapeutics in the 4th quarter worth $35,000. Finally, BNP Paribas Financial Markets bought a new position in Dianthus Therapeutics in the 4th quarter worth $59,000. 47.53% of the stock is owned by hedge funds and other institutional investors.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.